clesacostat   Click here for help

GtoPdb Ligand ID: 12242

Synonyms: PF-05221304 | PF05221304
Compound class: Synthetic organic
Comment: Clesacostat (PF-05221304) is an acetyl-CoA carboxylase (ACC) inhibitor [3]. It was designed to treat non-alcoholic steatohepatitis (NASH) by targeting disordered lipid metabolism in the liver.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 114.62
Molecular weight 502.56
XLogP 4.38
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc(cc(n1)c1ccc(cc1)C(=O)O)C(=O)N1CCC2(CC1)CC(=O)c1c(C2)cnn1C(C)C
Isomeric SMILES CC(C)n1c2c(CC3(CCN(CC3)C(=O)c3cc(nc(c3)OC)c3ccc(cc3)C(=O)O)CC2=O)cn1
InChI InChI=1S/C28H30N4O5/c1-17(2)32-25-21(16-29-32)14-28(15-23(25)33)8-10-31(11-9-28)26(34)20-12-22(30-24(13-20)37-3)18-4-6-19(7-5-18)27(35)36/h4-7,12-13,16-17H,8-11,14-15H2,1-3H3,(H,35,36)
InChI Key LXZMHBHEXAELHH-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Clesacostat (PF-05221304) has progressed to clinical evaluation. It is being investigated as a monotherpay and in combination with the DGAT2 inhibitor ervogastat.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04321031 Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) Phase 2 Interventional Pfizer 1
NCT03776175 A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease. Phase 2 Interventional Pfizer 2
NCT04399538 Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis Phase 2 Interventional Pfizer